Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment

European Journal of Surgical Oncology

Volumn 34, Issue 12, 2008, Pages 1316-1321

  Kornmann, M ^a   Formentini, A ^a   Ette, C ^a   Henne Bruns, D ^a   Kron, M ^b   Sander, S ^b   Baumann, W ^c   Kreuser, E D ^c   Staib, L ^c   Link, K H ^c  

^a Visceral   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c Asklepios Paulinen Klinik   (Germany)

Author keywords

5 FU; Adjuvant treatment; Colon cancer; Prognostic factors

Indexed keywords

ALPHA INTERFERON; FLUOROURACIL; FOLINIC ACID; LEVAMISOLE;

ADD ON THERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLON ADENOCARCINOMA; COLON CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DRUG DOSE INCREASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADENOCARCINOMA; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; DRUG THERAPY, COMBINATION; FLUOROURACIL; FOLLOW-UP STUDIES; GERMANY; HUMANS; IMMUNOLOGIC FACTORS; INCIDENCE; INTERFERON-ALPHA; LEUCOVORIN; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; VITAMIN B COMPLEX;

EID: 54849436682     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2008.01.019     Document Type: Article

References (23)

1. Benson III A.B. New approaches to the adjuvant therapy of colon cancer. Oncologist 11 (2006) 973-980
2. Benson III A.B., Schrag D., Somerfield M.R., et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22 (2004) 3408-3419
3. Twelves C., Wong A., Nowacki M.P., et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352 (2005) 2696-2704
4. Andre T., Boni C., Mounedji-Boudiaf L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350 (2004) 2343-2351
5. de Gramont A., Tournigand C., Andre T., Larsen A.K., and Louvet C. Adjuvant therapy for stage II and III colorectal cancer. Semin Oncol 34 (2007) S37-S40
6. Gill S., Loprinzi C.L., Sargent D.J., et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?. J Clin Oncol 22 (2004) 1797-1806
7. Link K.H., Kornmann M., Staib L., et al. Increase of survival benefit in advanced resectable colon cancer by extent of adjuvant treatment: results of a randomized trial comparing modulation of 5-FU + levamisole with folinic acid or with interferon-alpha. Ann Surg 242 (2005) 178-187
8. Kolonkarzinom J.T. In: Deutsche Krebsgesellschaft E.V. (Ed). Kurzgefasste interdisziplinäre Leitlinien 2002. Diagnostik und Therapie maligner Erkrankungen (2002), W. Zuckschwerd-Verlag, Munich 160-171
9. Staib L., Link K.H., and Beger H.G. Toxicity and effects of adjuvant therapy in colon cancer: results of the German prospective, controlled randomized multicenter trial FOGT-1. J Gastrointest Surg 5 (2001) 275-281
10. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 894 (2000), World Health Organization 1-253
11. Wittekind C., and Wagner G. TNM classification of malignant tumors. 5th ed. (1997), Springer, Berlin
12. O'Connell J.B., Maggard M.A., and Ko C.Y. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96 (2004) 1420-1425
13. Greene F.L., Stewart A.K., and Norton H.J. A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients. Ann Surg 236 (2002) 416-421
14. Prandi M., Lionetto R., Bini A., et al. Prognostic evaluation of stage B colon cancer patients is improved by an adequate lymphadenectomy: results of a secondary analysis of a large scale adjuvant trial. Ann Surg 235 (2002) 458-463
15. Neugut A.I., Matasar M., Wang X., et al. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol 24 (2006) 2368-2375
16. Rabeneck L., Davila J.A., Thompson M., and El-Serag H.B. Surgical volume and long-term survival following surgery for colorectal cancer in the Veterans Affairs Health-Care System. Am J Gastroenterol 99 (2004) 668-675
17. Meyerhardt J.A., Catalano P.J., Schrag D., et al. Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence. Ann Intern Med 139 (2003) 649-657
18. Ptok H., Marusch F., Kuhn R., et al. Influence of hospital volume on the frequency of abdominoperineal resections and long-term oncological outcomes in low rectal cancer. Eur J Surg Oncol 33 (2007) 854-861
19. Meyerhardt J.A., Catalano P.J., Haller D.G., et al. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer 98 (2003) 484-495
20. Dignam J.J., Polite B.N., Yothers G., et al. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst 98 (2006) 1647-1654
21. Sparreboom A., Wolff A.C., Mathijssen R.H., et al. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol 25 (2007) 4707-4713
22. Haller D.G., Catalano P.J., MacDonald J.S., et al. Fluorouracil (FU), Leucovorin (LV) and Levamisole (LEV) adjuvant therapy for colon cancer: five year final report of INT-0089. Proc Am Soc Clin Oncol 17 (1998) 256
23. O'Connell M.J., Laurie J.A., Kahn M., et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16 (1998) 295-300